Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature

Table 3 Response rates and survival rates with erlotinib following gefitinib therapy

Ref.	RR	DCR	PFS	OS
Cho et al[19]	9.50%	28.60%	60 d	158 d
Costa et al[23]			2 mo
Lee et al[21]	4.30%	8.70%
Vasile et al[22]	25%	62.50%	5.9 mo	14.6 mo
Wong et al[20]		35.70%	97 d
Sim et al[24]		25%	1.7 mo
Zhou et al[25]	9.50%	28.50%	55 d	135 d
Wong et al[26]		57.10%	14.9 wk	40 mo
Asami et al[27]	2.40%	59.50%	3.4 mo	7.1 mo
Hata et al[29]	9%	44%	2 mo	11.8 mo
Song et al[39]	0	35%	31 d	4.2 mo
Saito et al[41]		38.10%		369 d
Koyama et al[43]	7.40%	63.00%	135 d	333 d

RR: Response rate; DCR: Disease control rate; PFS: Progression free survival: OS: Overall survival.